MolNFT v1 · #95527 · protein
Crystal structure of the Fab fragment of 1C2, a monoclonal antibody specific for poly-glutamine
4ISV · 1C2 Fab light chain: “Crystal structure of the Fab fragment of 1C2, a monoclonal antibody specific for poly-glutamine”. X-ray diffraction, 5 pockets (best druggability 0.65). MolNFT v1 #95527 on GenesisL1: 3D structure, binding…
- PDB
- 4ISV
- Type
- protein
- Length
- 429 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- 1C2 Fab light chain; 1C2 Fab heavy chain
- Pockets
- 5 · best druggability 0.65
Structure
x-ray diffraction · 2 distinct chains · 9% helix, 56% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | 1C2 Fab light chain | protein | 217 | 7% helix, 57% strand | — |
| B | 1C2 Fab heavy chain | protein | 212 | 10% helix, 54% strand | — |
Pockets
5 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 622 | 0.65 | 0.75 | 59 | empty |
| 2 | 80 | 0.33 | 0.75 | 20 | empty |
| 3 | 75 | 0.32 | 0.74 | 17 | empty |
| 4 | 70 | 0.28 | 0.72 | 16 | empty |
| 5 | 56 | 0.27 | 0.73 | 14 | empty |
Interfaces
1 interface between chains.
- A–B · 1792 Ų buried · 19 hydrogen bonds · protein-protein
Modifications
Observed in the structure: 4 disulfide (disulfide).
Compared structures
- 4ISV · Crystal structure of the Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC FOR… · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Elsewhere: RCSB PDB 4ISV · PDBe 4ISV
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.